Circio Holding is trading at NOK 13.08 (+9.73%) after announcing a research collaboration with Full Circles Therapeutics.
- Announced August 26, the collaboration combines circVec and C4DNA technology for in-vivo cell therapy.
- The August 25 extraordinary general meeting approved two new directors and renewed share-issuance authority.
- The company-specific developments appear to be sustaining strong speculative biotech interest after recent sharp gains.